Novartis UKselect country select business contact A A A Countries Argentina Australia Austria Bangladesh Belgium Brazil Canada Chile China Denmark Egypt Finland France Germany Greece Hong Kong Hungary Indonesia Italy Japan Korea Mexico Netherlands Norway Philippines Poland Portugal Russia Spain Sweden Switzerland Taiwan Turkey United Kingdom USA Venezuela Businesses Novartis Pharmaceuticals Novartis Oncology Novartis Vaccines Sandoz (generics) Alcon Over-the-Counter Other websites Novartis Global Novartis Institutes for BioMedical Research Novartis Foundation for Sustainable Development General contact Novartis Pharmaceuticals UK Limited UK Head Office Frimley Business Park Frimley Camberley Surrey GU16 7SR +44 1276 692255 +44 1276 692508 Monday - Friday, 8:30 - 17:30 More information Investors Novartis International AG Investor Relations P.O. Box CH-4002 Basel Switzerland +41 61 324 79 44 investor.relations@novartis.com More information Media Novartis UK Press Office Press Office enquiries only +44 1276 698691 press.office@novartis.com More information Reporting side effects Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine. More information Product Information For enquiries contact +44 1276 698 370 medinfo.uk@novartis.com HOME ABOUT NOVARTIS ABOUT NOVARTIS HOME OUR MISSION NOVARTIS IN THE UK NOVARTIS AROUND THE WORLD COMPANY HISTORY AWARDS INVESTORS OUR PRODUCTS OUR PRODUCTS HOME OUR THERAPY AREAS ALCON PHARMACEUTICALS SANDOZ CORPORATE RESPONSIBILITY CORPORATE RESPONSIBILITY HOME ACCESS TO HEALTHCARE RESPONSIBLE BUSINESS PRACTICES PARTNERSHIPS AND SUPPORT INNOVATION INNOVATION HOME INNOVATION AT NOVARTIS RESEARCH & DEVELOPMENT INNOVATION FOR THE DEVELOPING WORLD ANIMALS AND RESEARCH NEWS NEWS HOME FEATURED UK NEWS UK NEWSROOM MEDIA CONTACTS GLOBAL MEDIA RELEASES CAREERS CAREERS HOME JOIN OUR TEAM MEET OUR PEOPLE CHOOSE US JOB SEARCH INTERNATIONAL BIOCAMP search Our new Corporate Brochure Did you know that Novartis UK funds 10% of pharmaceutical industry sponsored phase II-IV clinical trials? Or that Alcon is the UK's number one contact lens company? Find out more about who we are, what we do and why we do it, here, in our new Corporate Brochure. News Novartis' new heart failure medicine Entresto™ (sacubitril valsartan) recommended by CHMP for EU approval 29 Sep 2015 Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Entresto™ (sacubitril valsartan). Pending final approval by the European Commission (EC), Entresto (sacubitril valsartan), previously known as LCZ696, will be licensed for use in the UK for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (HFrEF). New heart failure medicine LCZ696 (sacubitril valsartan) to be available to the NHS under the Early Access to Medicines Scheme (EAMS) 2 Sep 2015 Novartis today announced that its investigational heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the Medicines and Healthcare products Regulatory Agency (MHRA) Early Access to Medicines Scheme (EAMS) for patients with significant unmet medical need. This allows LCZ696 (sacubitril valsartan) to be made available to eligible patients before a final European licensing decision is made. Cosentyx™ (secukinumab), an innovative new psoriasis treatment receives a final positive NICE recommendation 1 June 2015 The National Institute for Health and Care Excellence (NICE) has today issued a Final Appraisal Determination (FAD) recommending secukinumab for use on the NHS as an option for the treatment of adults with severe plaque psoriasis when - they have failed to respond to, are contraindicated to or cannot take standard systemic* therapies.1 Top Links SIX NYSE Stock performance Clinical Trials Job search Adverse event reporting Grant applications Contact us Product Information Leaflets (PILs) for patients Summary of Product Characteristics (SPC) for Healthcare Professionals Novartis country websites: Select by country Australia Austria Bangladesh Belgium Brazil Canada China Denmark Egypt Finland France Germany Greece Hong Kong Hungary Indonesia Italy Japan Korea Mexico Netherlands Norway Philippines Poland Portugal Russia Spain Sweden Switzerland Taiwan Turkey United Kingdom USA go Novartis business websites: Select by business Novartis Oncology Novartis Vaccines Novartis Diagnostics Sandoz (generics) Novartis Animal Health CIBA Vision Novartis Institutes for BioMedical Research Novartis Foundation for Sustainable Development go Worldwide offices Select an office Select an office © 2011 Novartis AG Terms of usePrivacy policy